TWST vs ILMN vs PACB

For growth investors, Twist Bioscience Corporation (TWST) is the stronger pick with 20.

3% revenue growth year-over-year, versus -23. 2% for Pacific Biosciences of California, Inc. (PACB). Illumina, Inc. (ILMN) offers the better valuation at 26. 2x trailing P/E (27. 5x forward), making it the more compelling value choice. Analysts rate Twist Bioscience Corporation (TWST) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Twist Bioscience Corporation (TWST) delivered a total return of -42.

9%, compared to -93. 0% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: TWST returned +325. 2% versus PACB's -80. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 23β versus Twist Bioscience Corporation's 2. 47β — meaning TWST is approximately 100% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Twist Bioscience Corporation (TWST) carries a lower debt/equity ratio of 29% versus 133% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Twist Bioscience Corporation (TWST) is pulling ahead at 20.

3% versus -23. 2% for Pacific Biosciences of California, Inc. (PACB). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 11. 6% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, TWST leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -201. 2% for Pacific Biosciences of California, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -308. 0% for PACB. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ILMN: 3.

4% to $147. 38.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Illumina, Inc.

(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23)). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +4. 3%, PACB: -80. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TWST is a small-cap high-growth stock; ILMN is a mid-cap quality compounder stock; PACB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.